Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: A medical chart review across ten centers in five European countries

Cancer Medicine

Volumn 3, Issue 6, 2014, Pages 1517-1526

  Porta, Camillo ^a   Levy, Antonin ^b   Hawkins, Robert ^c   Castellano, Daniel ^d   Bellmunt, Joaquim ^e   Nathan, Paul ^f   Mcdermott, Ray ^g   Wagstaff, John ^h   Donnellan, Paul ⁱ   Mccaffrey, John ^j   Vekeman, Francis ^k   Neary, Maureen P ^l   Diaz, Jose ^l   Mehmud, Faisal ^l   Duh, Mei Sheng ^m  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f MOUNT VERNON CANCER CENTRE   (United Kingdom)

^g ADELAIDE AND MEATH HOSPITAL   (Ireland)

^h SINGLETON HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL GALWAY   (Ireland)

^j MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^k GROUPE D ANALYSE   (Canada)

^l GLAXOSMITHKLINE   (United States)

^m ANALYSIS GROUP   (United States)

more..

Author keywords

Angiogenesis; Clinical observations; Statistical methods; Urological oncology

Indexed keywords

ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; SUNITINIB;

ADULT; AGED; CARCINOMA, RENAL CELL; CLINICAL TRIAL; COHORT ANALYSIS; EUROPE; FEMALE; HUMAN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; VASCULARIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; COHORT STUDIES; EUROPE; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84990978773     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.302     Document Type: Article

References (18)

1. Negrier, S., D. Perol, A. Ravaud, C. Chevreau, J. O. Bay, R. Delva, et al. 2007. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110:2468-2477.
2. Goodman, V. L., E. P. Rock, R. Dagher, R. P. Ramchandani, S. Abraham, J. V. Gobburu, et al. 2007. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 13:1367-1373.
3. Motzer, R. J., T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, et al. 2007. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356:115-124.
4. Motzer, R. J., T. E. Hutson, P. Tomczak, M. D. Michalson, R. M. Bukowski, S. Oudard, et al. 2009. Overall survival and updated results for sunitinib compared with interferon alfa in patient swith metastaic renal cell carcinoma. J. Clin. Oncol. 27:3584-3590.
5. Gore, M. E., C. Szczylik, C. Porta, S. Bracarda, G. A. Bjarnason, S. Oudard, et al. 2009. Safety and efficacy of sunitinib for metastatic renal cell carcinoma: an expanded-access trial. Lancet Oncol. 10:757-763.
6. Motzer, R. J., B. I. Rini, D. F. McDermott, B. G. Redman, T. Kuzel, M. R. Harrison, et al. 2014. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial. J. Clin. Oncol. 32:5s(Suppl.; abstract 5009).
7. Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (accessed 8 March 2012).
8. Ansari, J., A. Fatima, K. Fernando, S. Collins, N. D. James, and E. Porfiri. 2010. Sunitinib in patients with metastatic renal cell carcinoma: birmigham experience. Oncol. Rep. 24:507-510.
9. Hong, M. H., H. S. Kim, C. Kim, J. R. Ahn, H. J. Chon, S. J. Shin, et al. 2009. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res. Treat. 41:67-72.
10. Hwang, E., H. J. Lee, C. K. Sul, and J. S. Lim. 2010. Efficacy and safety of sunitinib on metastatic renal cell carcinoma: a single institution experience. Korean J. Urol. 51:450-455.
11. Yoo, C., J. E. Kim, J.-E. Lee, J.-H. Ahn, D. H. Lee, J.-S. Lee, et al. 2010. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn. J. Clin. Oncol. 40:980-985.
12. Choueiri, T. K., M. S. Duh, J. Clement, A. J. Brick, M. J. Rogers, C. Kwabi, et al. 2010. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety, and treatment patterns in clinical practice based on medical chart review. BJU Int. 105:1247-1254.
13. Choueiri, T. K., D. McDermott, M. S. Duh, S. P. Sarda, M. P. Neary, and W. K. Oh. 2010. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study. Urol. Oncol. 30:848-855.
14. Feinberg, B. A., P. Jolly, S. T. Wang, B. Fortner, J. Scott, J. Gilmore, et al. 2012. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med. Oncol. 29:786-794.
15. Porta, C., C. Paglino, I. Imarisio, C. Canipari, K. Chen, M. Neary, et al. 2011. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer. 11:105.
16. Houk, B. E., C. L. Bello, B. Poland, L. S. Rosen, G. D. Demetri, and R. J. Motzer. 2010. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother. Pharmacol. 66:357-371.
17. Motzer, R. J., T. E. Hutson, M. R. Olsen, G. R. Hudes, J. M. Burke, W. J. Edenfield, et al. 2012. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J. Clin. Oncol. 30:1371-1377.
18. Heng, D. Y., W. Xie, M. M. Regan, M. A. Warren, A. R. Golshayan, C. Sahi, et al. 2009. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27:5794-5799.